Relationship between polymorphism of N-acetyltransferase gene and susceptibility to colorectal carcinoma in a Chinese population

Pharmacogenetics

Volumn 8, Issue 6, 1998, Pages 513-517

  Lee, Edmund J D ^a   Zhao, Bin ^a   Seow Choen, Francis ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Colorectal carcinoma; N acetyltransferase 2; Polymorphism

Indexed keywords

ACYLTRANSFERASE;

ACETYLATION; ADULT; AGED; ARTICLE; CANCER SUSCEPTIBILITY; CHINESE; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID BASE SUBSTITUTION; POPULATION GENETICS; PRIORITY JOURNAL;

STAPHYLOCOCCUS PHAGE 187;

EID: 0032439841     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199812000-00008     Document Type: Article

References (24)

1. Blum M, Grant DM, McBride W, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990; 9:193-203.
2. Blum M, Demierre A, Grant DM, Hein M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 1991; 88:5237-5241.
3. Cartwright RA, Glasham RW, Rogers HJ, Ahmed RA, Hall DB, Higgins E, Kahn MA. The role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmaco-genetic epidemiological approach to bladder cancer. Lancet 1982; 2:842-846.
4. Deguchi T, Mashimo M, Suzuki T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J Biol Chem 1990; 265:12757-12760.
5. Ebisawa T, Deguchi T. Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferases. Biochem Biophys Res Commun 1991; 177:1252-1257.
6. Evans DAP, Manley KA, Mckusick VA. Genetic control of isoniazid metabolism in man. Br Med 1960; 2:485-461.
7. Evans DAP. N-acetyltransferase. In: Kalow, W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press; 1992. pp. 95-178.
8. Flammang TJ, Kadlubar FF. Acety coenzyme A-dependent metabolic activation of N-hydroxy-3, 2′-dimethyl-4-aminobiphenyl and several carcinogenic N-hydroxy arylamines in relation to tissue and species differences, other acyl donors, and arylhydroxamic acid-dependent acyltransferases. Carcinogenesis 1986; 7:919-926.
9. Graf T, Broly F, Hoffmann F, Probst M, Meyer UA, Howald H. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers. Eur J Clin Pharmacol 1992; 43:399-403.
10. Grant DM. Molecular genetics of the acetyltransferases. Proceedings of the 10th International Symposium on Microsomes and Drug Oxidations, 1994; Toronto, Canada, pp. 12-14.
11. Hein DW. Acetylator genotype and arylamine-induced carcinogenesis. Biochem Biophys Acta 1988; 948:37-66.
12. Hickman D, Sim E. N-acetyltransferase polymorphism: comparison of phenotype and genotype in humans. Biochem Pharmacol 1991; 42:1007-1014.
13. Ilett KF, David BM, Detchon P, Castleden WM, Kwa R. Acetylation phenotype in colorectal carcinoma. Cancer Res 1987; 47:1466-1469.
14. Ladero JM, Gonzalez JF, Benitez J, Vargas E, Fernandez MJ, Baki W, Diaz-Rubio M. Acetylator polymorphism in human colorectal carcinoma. Cancer Res 1991; 51:2098-2100.
15. Lang NP, Chu DZJ, Hunter CF, Kendall DC, Flammang TJ, Kadlubar FF. Role of aromatic amine acetyltransferase in human colorectal cancer. Arch Surg 1986; 121:1259-1261.
16. Lee EJD, Zhao B, Moochhala SM, Ngoi SS. Frequency of CYP1A1, NAT2 and GSTM1 alleles in a normal Chinese population. Pharmacogenetics 1994; 4:355-358.
17. Mommsen S, Barford NM, Aagaard J. N-acetyltransferase phenotypes in the urinary bladder carcinogenesis of a low risk population. Carcinogenesis 1985; 6:199-201.
18. Roots I, Drakoulis N, Brockmoller J, Janicke I, Cuprunov M, Ritter J. Hydroxylation and acetylation phenotypes as genetic risk factors in certain malignancies. In: Kato R, Estabrook RW, Cayen MN, editors. Xenobiotic metabolism and disposition. London: Taylor & Francis; 1989. pp. 499-506.
19. Roots I, Drakoulis N, Brockmoller J. Polymorphic enzymes and cancer risk: Concepts, methodology and data review. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press, Inc.; 1992. pp. 815-841.
20. Rothman N, Hayes RB, Bi W, Caporaso N, Broly F, Woosley RL, et al. Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males. Pharmacogenetics 1993; 3:250-255.
21. Shibuta K, Nakashima T, Abe, M., Mashimo M, Mori M, Ueo H, et al. Molecular genotyping for N-acetylation polymorphism in Japanese patients with colorectal cancer. Cancer 1994; 74:3108-3112.
22. Vatsis KP, Martell KJ, Weber WW. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc Natl Acad Sci USA 1991; 88:6333-6337.
23. Weber WW, Mein DW. N-Acetylation pharmacogenetics. Pharmacol Rev 1985; 37:25-79.
24. Wohlleb JC, Hunter CF, Blass B, Kadlubar FF, Chu DZJ, Lang NP. Aromatic amine acetyltransferase as a marker for colorectal cancer: environmental and demographic associations. Int J Cancer 1990; 46:22-30.